ROS scavengers and siRNA-mediated knockdown of the mitochondrial protease OMA1 inhibited OPA1 cleavage and cell death, providing evidence for ROS-targeted therapies in refractory pediatric T-ALL (49). This evidence concerns the gene OMA1 and acute lymphoblastic leukemia.